| Latest | F'cast | |
|---|---|---|
| Div Yield | 0.0% | 0.0% |
| Div Cover | n/a | n/a |
| Op Mrgn | 6.5% | n/a |
| ROCE | 10.2% |
| Latest | F'cast | |
|---|---|---|
| P/E | 29.3 | n/a |
| PEG | 0.9 | n/a |
| Pr/Revenue | 0.7 | n/a |
| Pr/Book | 0.7 |
| Latest | F'cast | |
|---|---|---|
| Revenue | 10.0% | n/a |
| PBT | 30.8% | n/a |
| EPS | 30.9% | n/a |
| DPS | n/a | n/a |
| Year Ending | Revenue (£m) | Pre-tax (£m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 31-Mar-22 | 82.19 | 1.39 | (1.01)p | n/a | n/a | n/a | n/a | 0.0% |
| 31-Mar-23 | 85.31 | 5.10 | 1.49p | 64.8 | n/a | n/a | n/a | 0.0% |
| 31-Mar-24 | 89.42 | 2.97 | 1.55p | 55.2 | 13.8 | +4% | n/a | 0.0% |
| 31-Mar-25 | 79.60 | 4.46 | 2.49p | 21.5 | 0.4 | +61% | n/a | 0.0% |
| 31-Mar-26 | 87.53 | 5.83 | 3.26p | 29.3 | 0.9 | +31% | n/a | 0.0% |
a. Based on UK GAAP presentation of accounts - includes discontinued activities
| Exclusive in-licensing agreement with Vaxinano | 12-Aug-2026 | 07:00 | RNS |
| Posting of Annual Report and Notice of AGM | 05-Aug-2026 | 11:32 | RNS |
| Holding(s) in Company | 28-Jul-2026 | 09:12 | RNS |
No deals were found in the last 28 days.
| Currency | UK Pounds |
| Share Price | 102.50p |
| Change Today | 0.000p |
| % Change | 0.00 % |
| 52 Week High | 114.00 |
| 52 Week Low | 73.00 |
| Volume | 107,124 |
| Shares Issued | 67.76m |
| Market Cap | £69.45m |
| Beta | 0.01 |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income | ![]() |
|---|
| Growth |
|
|---|
| Latest | Previous | |
|---|---|---|
| Final | Final | |
| Ex-Div | 23-Sep-21 | 26-Sep-19 |
| Paid | 22-Oct-21 | 16-Oct-19 |
| Amount | 1.00p | 7.04p |
| Time | Volume / Share Price |
| 09:23 | 50,000 @ 102.50p |
| 16:01 | 7,150 @ 102.50p |
| 16:01 | 122 @ 102.50p |
| 15:44 | 2,500 @ 102.50p |
| 15:44 | 4,413 @ 100.81p |
| CFO | Christopher Wilks |
| CEO | David Hallas |
You are here: research